Independent AI index
for professionals

Home / Safety / Gemini for the pharmaceutical industry

Google

How safe is Gemini for the pharmaceutical industry?

GDPR profileOur summary of what the provider itself publishes about your data: EU hosting possible, no training on your data for business use, and self-hostable. Caution is given to a model with a documented issue, such as an investigation by a regulator. How we measure for the pharmaceutical industryStrong

Gemini has a strong published GDPR profile and, with the right business settings, is well suited to the pharmaceutical industry.

Where does Gemini stand in the pharmaceutical industry?

Shared place 1 of 25 options for the pharmaceutical industry (professional tools and general assistants) on GDPR profile. 5 options, like Gemini's profile, are Strong. Each tile is an option we track for this field; click through for the check.

Strong5
Good3
Limited7
Unknown3
Caution7

Published safeguards

✓EU hosting possibleYes
✓No training on your data (business)Yes
–Self-hostable (on-premise)Not known

Via Vertex AI, processing can be pinned to EU regions (including the Netherlands). Enterprise data is not used for training; the free consumer app offers fewer guarantees (though stricter policies apply for the EU/EEA).

How to use Gemini safely

  • Use the business variant and sign a data processing agreement (DPA).
  • Do not enter unnecessary personal data into prompts; anonymise where possible.
  • Enable EU data residency where the provider offers it.
  • Keep a professional in the loop: in this sector it concerns health data of trial participants and patients (special category personal data under art.

Stronger or equally strong in the pharmaceutical industry

CradleCradle (Amsterdam, the Netherlands and Zürich, Switzerland)CastorCastor (Amsterdam, Netherlands)BiolevateBiolevate (Paris, France)Aily LabsAily Labs GmbH (Munich, Germany)ClaudeAnthropic

Latest developments

18 September 2026Plugin4Shell: Google does not patch Gemini CLI and writes off the product

When Plugin4Shell was published on 18 September 2026, it emerged that Google had chosen not to fix the vulnerability in Gemini CLI. On 4 August 2026, Google announced that Gemini CLI is being discontinued and referred users to Antigravity. The result: any remaining Gemini CLI installation with plugins stays permanently vulnerable to zero-click code execution via a modified plugin repository. GDPR relevance: no update-based mitigation is available, so the only defensible measure is to migrate or remove the tool from machines holding personal data, source code or credentials (art. 32 GDPR). This concerns only the CLI tool, not the Gemini API or Gemini in Google Workspace. source

Questions

How safe is Gemini for the pharmaceutical industry?
Gemini has a strongly published GDPR profile and, with the right business settings, is well suited to use in the pharmaceutical industry. EU options, no training on your data and/or self-hostable.
Does Gemini train on my data?
Via Vertex AI, processing can be pinned to EU regions (including the Netherlands). Enterprise data is not used for training; the free consumer app offers fewer guarantees (though stricter policies apply for the EU/EEA).
What should I look out for with AI in the pharmaceutical industry?
This sector involves health data of trial participants and patients (special category personal data under Article 9 GDPR) and confidential research data. Ask every provider where the data is stored and whether it is used to train models: Castor hosts in the Netherlands (Google Cloud europe-west4) and does not share data or models between customers, Cradle states that source data never goes to third-party AI models, Iris.ai hosts on AWS in Ireland and Germany. Biolevate and Ennov also run in private cloud or on-premises. With Veeva Vault AI and Yseop, texts go to Anthropic models via Amazon Bedrock; check the region and the data processing agreement. If you work in GxP processes, an AI tool must also be validated (EU GMP Annex 11) and a competent employee remains responsible. For AI in medicines development, the EMA has a reflection paper (2024) and is working with the FDA on joint principles.

Source documents

ai.google.devcloud.google.com

Everything about Gemini Best AI for the Pharmaceutical Industry

Summarised by the editorial team from provider documentation · not legal advice

Last checked: 16 October 2026 · How we check

Next stepAll 25 options for pharmaceutical industryProfessional tools and general assistants side by side, on GDPR profile, price and quality.

Every Friday: what changed in AI for the pharmaceutical industry

New models, prices, oversight and tools, with sources and what it means for you. One email a week, unsubscribe with one click.

View a sample

We only use your address for this newsletter. You confirm first by email.